NCT01876511View on ClinicalTrials.gov

Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)

PHASE2CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2019

Conditions
MSI Positive Colorectal CancerMSI Negative Colorectal CancerMSI Positive Non-Colorectal Cancers
Interventions
DRUG

MK-3475

MK-3475 10 mg/kg every 14 days

Trial Locations (7)

15232

University of Pittsburgh Cancer Institute, Pittsburgh

19104

University of Pennsylvania, Abramson Cancer Center, Philadelphia

20892

Investigator Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, NIH, Bethesda

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

43210

Ohio State University, Columbus

94305

Stanford University, Stanford

97213

Providence Portland Medical Center, Portland

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT01876511 - Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C) | Biotech Hunter | Biotech Hunter